skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Early efficacy of dexamethasone implant (OZURDEX ® ) in diabetic macular edema: Real life study

Journal francais d'ophtalmologie, 2017-05, Vol.40 (5), p.408-413 [Peer Reviewed Journal]

Copyright © 2017 Elsevier Masson SAS. All rights reserved. ;EISSN: 1773-0597 ;DOI: 10.1016/j.jfo.2016.10.017 ;PMID: 28336283

Full text available

Citations Cited by
  • Title:
    Early efficacy of dexamethasone implant (OZURDEX ® ) in diabetic macular edema: Real life study
  • Author: Sarda, V ; Fajnkuchen, F ; Nghiem-Buffet, S ; Grenet, T ; Chaine, G ; Giocanti-Auregan, A
  • Subjects: Aged ; Dexamethasone - administration & dosage ; Dexamethasone - adverse effects ; Diabetic Retinopathy - drug therapy ; Drug Implants - adverse effects ; Female ; Glucocorticoids - administration & dosage ; Glucocorticoids - adverse effects ; Humans ; Intravitreal Injections ; Macular Edema - drug therapy ; Male ; Middle Aged ; Retrospective Studies ; Treatment Outcome ; Visual Acuity - drug effects
  • Is Part Of: Journal francais d'ophtalmologie, 2017-05, Vol.40 (5), p.408-413
  • Description: To assess early efficacy of dexamethasone intravitreal implant 0.7mg (OZURDEX ) at the time of peak efficacy (2 months after injection) in patients with decreased visual acuity secondary to diabetic macular edema (DME). Retrospective monocentric study. Inclusion criteria were best-corrected visual acuity (BCVA)≤70 letters (20/40) due to DME and central retinal thickness (CRT)≥300 microns (Cirrus 2, Carl Zeiss Meditec, Inc, Dublin). Enrolled patients could be treatment naive or not (after failure of laser photocoagulation and/or anti-VEGF therapy). Follow-up was at least 6 months. Our primary endpoint was BCVA gain at M2 after injection. Secondary endpoints were best-corrected visual acuity at 2 and 4 months, central retinal thickness at 2 and 4 months, mean interval between 2 injections, and adverse events. Nineteen eyes of 19 patients were included in this study. The mean age was 67.45 years, sex ratio was 2.17 men/women, and the patients were all type 2 diabetics. Three of 19 patients were treatment naive for anti-VEGF intravitreal injection, and 52.3% were pseudophakic (10/19 patients). The mean gain of BCVA at M2 was +7.7 letters. The mean BCVA was 51.1 ETDRS letters at baseline and 58.8 at M2. Mean CRT was 568.9μm at baseline and 291.2μm at M2. Treatment with dexamethasone implant was mainly a second-line treatment after failure of other treatments (macular laser photocoagulation and/or intravitreal injection of anti-VEGF). Three patients were naive of anti-VEGF treatment. Intraocular pressure≥25mmHg was found in 2 patients, and controlled medically. No glaucoma surgery was performed. The dexamethasone implant (OZURDEX ) allows an anatomical and functional improvement in patients suffering from vision loss due to DME. In this series, the implant was well tolerated.
  • Publisher: France
  • Language: French
  • Identifier: EISSN: 1773-0597
    DOI: 10.1016/j.jfo.2016.10.017
    PMID: 28336283
  • Source: MEDLINE
    Alma/SFX Local Collection
Back to results list
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait